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Background: This study aims to evaluate the effectiveness of aripiprazole augmentation of maintenance treatment
for bipolar disorder in patients with minor or subsyndromal mood episodes while on a stable dose of a mood
stabiliser and/or antidepressant.
Methods: All subjects had a diagnosis of bipolar I or II disorder (Diagnostic and Statistical Manual of Mental
Disorders-4th Edition, Text Revision). Open-label aripiprazole was given over 8 weeks initially. The starting dose was
5 to 15 mg/day with a mean final dose of 11.5 mg (±4.6). Patients were assessed at weeks 0, 2, 4 and 8 with the
Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS) and Clinical Global
Impression of Severity (CGI-S).
Results and discussion: Seventeen of 20 (85%) patients completed week 4, while 14 (70%) patients completed
8 weeks. For intention-to-treat data, there was a significant decrease in MADRS scores over the course of treatment,
with a reduction of 6.40 points at endpoint (p < 0.0005). Improvement from baseline was significant at week 2 and
remained through to week 8. Similarly, CGI-S scores significantly decreased over the course of study, but not YMRS
scores. Aripiprazole was shown to be a modestly effective augmentation therapy for depressive symptoms in
bipolar I and II in this small open-label study.
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Increasingly, patients suffering from bipolar disorder are
being treated with atypical antipsychotics (AAP). Most
evidence available for their use stems from monotherapy
studies of bipolar I patients who are either experiencing
a manic or major depressive episode. In practice, AAPs
are most often used in combination with the more trad-
itional mood stabilisers as the majority of bipolar pa-
tients respond inadequately to monotherapy alone. Cruz
et al. (2012) systematically reviewed published or regis-
tered double-blind randomised controlled trials (RCTs)
using modern antipsychotics in bipolar I/II depressive
patients. They identified five RCTs; four involved* Correspondence: jsarris@unimelb.edu.au
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in any medium, provided the original work is pantipsychotic monotherapy and the other used both
monotherapy and combination with an antidepressant.
They concluded that only quetiapine and olanzapine
have demonstrated efficacy in bipolar depressive pa-
tients, with this effect occurring rapidly from week 1 on-
wards. Studies exploring the use of AAPs in rapid
cycling bipolar disorder are lacking, and their efficacy to
stabilise mood via maintenance therapy has not yet been
demonstrated (Zupancic 2011).
In a recent report from the STEP BD project, Goldberg
et al. (2009) found that 67% of bipolar subjects were on
two or more psychotropics, 40% of subjects received three
or more psychotropic medications, while 18% of patients
were taking four or more. Several international practice
guidelines also recommend the optimal use of combin-
ation therapy to control both manic and depressive epi-
sodes in bipolar disorder (APA 2002; Yatham et al. 2009).
Combining a mood stabiliser with an AAP may haves is an Open Access article distributed under the terms of the Creative Commons
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the additional side effect burden. These include extrapyr-
amidal side effects and long-term metabolic and endocrine
abnormalities. As Liauw and McIntyre (2010) comment,
AAPs may evoke a different array of treatment-emergent
adverse events than conventional agents; however, they do
offer an improved therapeutic index when compared to
conventional pharmacotherapies in bipolar disorder.
A further clinical consideration involves the potential
pharmacokinetic interaction which can occur between an-
tiepileptics and second-generation antipsychotics such as
aripiprazole (de Leon et al. 2012). Additional human stud-
ies and post-market surveillance are advised to clarify the
safety of combining aripiprazole with antiepileptics such
as carbamazepine.
In several double-blind randomised controlled studies
of acute mania, combinations of lithium or divalproex
with the AAPs risperidone, quetiapine, olanzapine and
aripiprazole have demonstrated significant beneficial ef-
fects compared with lithium or divalproex monotherapy.
In fact, for severe manic states, combination therapy is
recommended as a first-line treatment (Yatham et al.
2009; Ketter 2008). For maintenance treatment in bipo-
lar disorder patients who responded acutely to the
addition of quetiapine to lithium or divalproex, continu-
ing this combination reduced the subsequent risk of re-
lapse to depression, mania or mixed states compared to
lithium or divalproex alone (Suppes et al. 2009). Com-
parable data, however, are not available for combination
with other AAP (Yatham et al. 2005).
In bipolar depressed patients, the evidence for added
benefit from combination therapy with AAP has not
been well studied. There is only one small double-blind
randomised controlled study of aripiprazole as an aug-
mentation agent in bipolar disorder. Quante et al. (2010)
investigated 23 inpatients with Diagnostic and Statistical
Manual of Mental Disorders-4th Edition (DSM-IV)-di-
agnosed bipolar major depression (Hamilton Depression
Rating scale (HAM-D) ≥ 20) with a pre-existing stable
regimen of lithium or valproate for at least 1 week. After
inclusion, all patients were given adjunctive citalopram
and either aripiprazole (n = 12) or placebo (n = 12) for
6 weeks. After 6 weeks of treatment, both groups had a
significant reduction of HAM-D-rated depression of
−18.71 for aripiprazole and −15.33 for placebo; however,
this was not statistically significant between the groups.
A noted deficit of this pilot study was the small sample,
and as both groups responded well to citalopram, there
was little chance for augmentation with aripiprazole to
provide greater efficacy.
A common ongoing cause of suffering and disability in
bipolar disorder is residual symptoms, usually either
minor or subsyndromal depression (Strakowski 2007); it
is for these symptoms that augmentation with anotheragent such an AAP is often attempted but for which there
is virtually no data. Aripiprazole has a unique pharmaco-
logical mode of action that differs from current antipsy-
chotics. It is a partial agonist that modulates dopamine
activity (Yatham et al. 2005). Aripiprazole acts as a func-
tional antagonist in a hyperdopaminergic environment
and a functional agonist in a hypodopaminergic environ-
ment (Keck and McElroy 2003). There is evidence that
bipolar disorder is associated with an alteration of
the dopaminergic system, with increased dopamine func-
tion in mania and deficient function in depression (Keck
and McElroy 2003). As a partial D2 receptor agonist,
aripiprazole may therefore be well placed to correct
both a functional deficiency and overactivity. Moreover,
aripiprazole is also an antagonist at serotonin 5-HT2A re-
ceptors, a partial agonist at 5-HT1A receptors and an in-
hibitor of the 5-HT transporter (Yatham et al. 2005).
These properties of aripiprazole have been hypothesised
to mediate its putative antidepressant effects.
There is a need for further studies of AAP as combin-
ation or augmentation agents as they are more broadly
being used in bipolar disorders. Therefore, the aim of
this study was to evaluate the effectiveness of aripi-
prazole augmentation of maintenance treatment for bi-
polar disorder in patients with minor or subsyndromal
mood episodes while on a stable dose of mood stabiliser
and/or antidepressant.
Methods
All subjects were outpatients, aged 18 years and above
who had a diagnosis of bipolar I or II disorder confirmed
by the Structured Clinical Interview for DSM-IV Axis I
Disorders - Clinician Version. Patients were experien-
cing ongoing clinically significant symptoms but did not
meet the full DSM-IV TR criteria for either major de-
pressive episode or mania or mixed episode. All patients
had been on a stable dose of a mood stabiliser and/or
antidepressant at an adequate dose for at least 8 weeks
prior to study entry. At baseline, all patients were
interviewed and examined by a psychiatrist (IS or CN)
to determine the diagnosis and suitability for entry to
the study. Two research assistants who were trained in
the use of the scales and who were tested for inter-rater
reliability were used to assess the patients. All female pa-
tients of childbearing potential needed to use a medically
accepted means of contraception. All participants pro-
vided written informed consent and were able to under-
stand and comply with the requirements of the study.
The study was approved by the Research and Ethics
Committee at The Melbourne Clinic.
Patients who met one or more of the following criteria
at enrolment were excluded from the study: (1) use of
antipsychotic medication within 30 days of commence-
ment of study, (2) use of depot antipsychotics during the
Table 1 Baseline demographics and clinical features of
patients in study
Patient demographics and clinical features
Bipolar diagnosis, n (%)
Bipolar I 6 (30)
Bipolar II 14 (70)
Females, n (%) 10 (50)
Caucasians, n (%) 20 (100)
Age (years), mean (SD) 47.9 (12.4)
MADRS, mean (SD) 20.5 (7.8)
Range 6 to 36
YMRS, mean (SD) 7.5 (6.5)
CGI-S, mean (SD) 4.2 (0.7)
Range 2 to 5
Weight (kg), mean (SD) 89.6 (19.6)
Starting dose (mg), mean (SD) 8.8 (3.2)
Range 5 to 15
Endpoint dose (mg), mean (SD) 11.5 (4.6)
















Week 2 Week 4 Week 8
* P < 0.0005 over Time (ANOVA)
Figure 1 MADRS scores (means ± SD) from baseline to week 8.
An asterisk indicates p < 0.0005 over time (ANOVA).
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(4) current pregnancy or lactation, (5) current DSM-IV
substance or alcohol dependence, (6) unstable or inad-
equately treated clinically significant medical illness, (7)
current DSM-IV TR psychiatric diagnosis other than bi-
polar disorder and (8) significant risk for suicide.
Aripiprazole was administered in an open-label man-
ner at a starting dose of 5 to 15 mg/day at baseline.
After 2 weeks, the dose could be increased by 5 mg/day,
then by a further 5 mg/day at week 4 and a further
5 mg/day at week 6, to a maximum of 30 mg/day, as
clinically indicated. After week 8 of the study period, a
6-month extension period was permitted for those who
responded to the treatment provided they agreed to on-
going two monthly assessments. At completion of the
study or early termination, the dose was down-titrated if
on more than 15 mg/day. The dose was reduced by
10 mg/day over a week.
Patients were assessed at weeks 0, 2, 4 and 8 with the
Montgomery-Asberg Depression Rating Scale (MADRS),
Young Mania Rating Scale (YMRS) and Clinical Global
Impression of Severity (CGI-S). Tolerability was assessed
using the Simpson and Angus scale (SAS), the Barnes
Akathisia scale (BAS), the Abnormal Involuntary Move-
ments scale (AIMS) and reports of adverse events. The
changes in MADRS, YMRS and CGI-S scores from base-
line to week 8 were analysed using one-way repeated
measures analysis of variance (ANOVA) and last obser-
vation carried forward analysis. Responders as defined
by a ≥50% decrease in MADRS and remission as a
MADRS score of ≤8 were calculated.
Results
Twenty-one patients entered the study, and follow-up rat-
ings were available for 20 subjects. Patient demographics
and clinical features at baseline are listed in Table 1.
Seventeen (85%) patients completed week 4, while 14
(70%) patients completed 8 weeks. There were three (15%)
patients taking one or more mood stabiliser (carbamaze-
pine, lithium, valproate), 12 (60%) patients taking both a
mood stabiliser (carbamazepine, lamotrigine, lithium, val-
proate) and an antidepressant (escitalopram, fluvoxamine,
mirtazepine, moclobemide, tranylcypromine, sertraline,
venlafaxine), while five (25%) patients were taking only an
antidepressant (fluvoxamine, tranylcypromine, sertraline,
venlafaxine).
There was a significant decrease in MADRS scores over
the course of treatment (F = 11.17; df = 3, 17; p < 0.0005).
The improvement from baseline was significant at week 2
and remained so through to week 8 (Figure 1). On
intention-to-treat at study endpoint, pooled MADRS
scores reduced from 20.45(±7.78) to 14.05(±8.68),
with a reduction of 6.40 points. Similarly, CGI-S scores
significantly decreased over the course of study (F = 15.84;df = 3, 17; p < 0.0005), and again, this was significant from
week 2 through to week 8. No correlation was found be-
tween the dose of aripiprazole and reduction of MADRS
or CGI-S scores. There was no significant difference in
YMRS scores over the study. Observed case analysis
resulted in similar findings. Eight (40%) patients met
MADRS response criteria while seven (35%) patients were
classified as MADRS remitters at the last evaluation,
whereas seven (50%) of the 14 patients who completed
8 weeks were classified as both responders and remitters.
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amined separately, there was a significant improvement
in MADRS scores over the course of treatment (F =7.39;
df = 3, 11; p = 0.006). Improvement from baseline was
significant at week 2 and week 4, but not at week 8,
with a reduction of −5.07 on the MADRS from baseline
(p = 0.058). CGI-S was similarly significantly improved
from baseline to weeks 2 and 4, but not week 8. There
was no significant improvement for YMRS at any of the
time points. Response and remission rates were slightly
lower in the bipolar II group only.
One subject withdrew before week 2 due to flu-like
symptoms with no follow-up ratings. Three patients
discontinued their treatment before week 4 and a further
three before week 8 due to akathisia (1), agitation and
anxiety (1), mild hypomanic symptoms (2) and inad-
equate efficacy (2). There were no significant differences
in SAS, BAS or AIMS scores from baseline to week 8
either for the whole group or for the bipolar II group
only. Nine patients continued with aripiprazole following
the acute study. Two patients discontinued within the
first 2 months due to relapse, five maintained their im-
provement for 6 months, and a further two patients con-
tinued for 11 to 12 months.
Discussion
Aripiprazole was shown to be a modestly effective aug-
mentation therapy for depressive symptoms in bipolar I
and II disorders in this small open-label study. The pa-
tients in this sample did not meet DSM-IV criteria for a
major depressive episode or mania or hypomania but
were on stable maintenance medications with subopti-
mal mood symptom control. It is notable that aripi-
prazole was able to provide some improvement in this
sample that were nonetheless significantly depressed. In
our overall analysis, augmentation with aripiprazole did
not significantly lower YMRS from week 0 to 8, but this
is most likely due to the low mean YMRS of our patients
at baseline. However, there were four patients with high
YMRS at baseline (mean YMRS 19, range 16 to 22), and
all were improved at week 8 with a mean YMRS of 3
(range of 0 to 4).
There have been two large double-blind randomised
placebo-controlled trials of aripiprazole monotherapy in
patients suffering from bipolar I and experiencing a
major depressive episode (Thase et al. 2008). In both of
these studies, aripiprazole monotherapy was no more
effective than placebo at end point (week 8). The
aripiprazole-treated patients were significantly more im-
proved in the MADRS from weeks 1 to 6 for one study
and for weeks 1 to 3 and 5, but separation from placebo
was lost in the later weeks. The authors speculated that
the dosing regimen may have been too high (starting
dose of 10 mg) or titration was too rapid (5-mgincrements per week) for this patient group, resulting in
unexpectedly high rates of discontinuation. A meta-
analysis of these RCTs (n = 690) (Fountoulakis et al. 2011),
however, revealed a significant difference at week 8 in
favour of treatment over placebo (p = 0.038). Regardless,
the weak effect size of d = 0.17 and small relative reduc-
tion of −1.12 in the MADRS point to a limited benefit for
its use as a monotherapy in bipolar depression.
There have been six open-label case studies of ari-
piprazole augmentation in bipolar depression (Ketter
et al. 2006; Kemp et al. 2007; McElroy et al. 2007; Dunn
et al. 2008; Sokolski 2007; Mazza et al. 2008). Three of
the studies were retrospective chart reviews of patients
with treatment-resistant depression (Ketter et al. 2006;
Kemp et al. 2007; Sokolski 2007), and all but one study
included both bipolar I and II patients (Sokolski 2007).
Three studies included patients on aripiprazole mono-
therapy (McElroy et al. 2007; Dunn et al. 2008; Mazza
et al. 2008). All studies reported improvement in depres-
sive symptoms regardless of whether patients were on
monotherapy or augmentation with aripiprazole. Re-
sponse rates were 42% to 65% for the prospective
studies. The study reporting the highest percentage of
improvement (65%) was the largest (n = 85) and the lon-
gest (16 weeks) (Mazza et al. 2008). The most trouble-
some side effect was akathisia, ranging from 21% to 42%
of patients. Aripiprazole was well tolerated in this study
perhaps because of the low doses used with a mean final
dose of only 11.5 mg. Other open augmentation studies
found higher rates of akathisia than this study, which
may be due to the higher doses used.
Conclusions
Our study was limited by having an uncontrolled open-
label design and a small sample size, while the mainten-
ance therapies were also not standardised. Further, as
the sample was modest, we could not ascertain which
medications (as monotherapies or combinations) were
more effective in combination with aripiprazole. Regard-
less, this pilot study adds to the evidence base for the
potential utility of aripiprazole in both bipolar I and II
patients who have ongoing subsyndromal depressive
symptoms rather than suffering from a major depressive
episode. Minor and subsyndromal depressive episodes
continue to be the most common symptoms affecting bi-
polar patients and lead to significant impoverishment of
quality of life and disability (Judd et al. 2002).
The implications of this study for supporting longer-
term adjunctive treatment of aripiprazole in bipolar
disorder are unknown. As this study and previous ad-
junctive trials are typically conducted over 6- to 8-week
periods, longer-term studies are required to establish
whether effectiveness of using aripiprazole may continue
in this population. Of note, in our study, the main effect
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effect slightly diminishing from week 4 to week 8. This
reflects the conclusions of Cruz et al. (2012) who found
that both aripiprazole trials reviewed failed on the pri-
mary efficacy measure after the first 6 weeks.
Ideally, this study should be replicated without the
above confounding variables and methodological defi-
ciencies. Even though AAPs will continue to have an im-
portant role in bipolar disorders, either in combination or
as an augmentation agent, the conduct of rigorous studies
may be hampered by the complex study designs and large
samples required, with potentially untenable financial
implications. Although our study provides a positive signal
for aripiprazole as a potential efficacious augmenting
agent, the evidence is not conclusive, and it is premature
to apply clinical recommendation at this stage.
Key points
The following are highlights from the study:
 Aripiprazole was shown to be a modestly effective
augmentation therapy for depressive symptoms in
bipolar I and II disorders in this small open-label
study.
 Although our study provides a positive signal for
aripiprazole as a potential efficacious augmenting
agent, the evidence is not conclusive, and it is
premature to apply clinical recommendation at this
stage.
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